The main objects include: liquid biopsy detection of circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor exosomes (exosome), which originates from the tumor tissue in and present the blood, can prompt tumor progression and drug resistance, guide individual treatment. Compared with the existing detection methods of tumor biopsy, liquid biopsy is non-invasive, can be frequent detection and rapid response capability are reflected in a significant advantage, with huge potential for development.
Exosomes are small membrane vesicles (30–120 nm) after the fusion of multivesicular bodies and cell membrane and releasion into the extracellular matrix. Exosomes were first discovered by Johnstone and other researchers in the study of from reticulocytes to mature red blood cell transformation process. After years of research, scientists have found that exosome had a wide range of sources, in addition to reticulocytes, blood cells such as T cells, B cells, platelets, dendritic cells, mast cells and non-blood cells such as epithelial cells, tumor cells could secrete exosome, then exosome will be released into a variety of body fluids such as amniotic fluid, ascites, nasal irrigation fluid, saliva, serum, plasma, milk, urine, cerebrospinal fluid, etc., through the circulatory system to reach other cells and tissues, resulting in remote regulation
The first “national public entrepreneurship peoples innovation activities week” (called double week), the launching ceremony was held in the city throughout the country on the morning of 19, the theme of
In August 18th, Thermo Fisher Scientific and Shanghai Biotecan Pharmaceuticals Corporation (called
First Shanghai Centre, 180 Zhangheng Rd., Pudong New District, Shanghai, China